- letzte 200 News
- Archiv
| Zeit | Aktuelle Nachrichten | Rating | Leser | ||
|---|---|---|---|---|---|
| 10.02. | EnSilica (LSE:ENSI) - commercial momentum should support rapid scaling in revenues. | 238 | EnSilica's H1 FY25 results demonstrate robust commercial and operational progress, masked by a 3% revenue dip to £9.3 million. However, mix improved substantially, with chip supply revenue grew 164%... ► Artikel lesen | ||
| 06.02. | Basilea Pharmaceutica - Encouraging start to the year for Cresemba | 373 | Basilea Pharmaceutica has continued its strong momentum into 2025, announcing the receipt of a CHF1.2m milestone payment for Cresemba for the strategically important Japanese market. This marks the... ► Artikel lesen | ||
| 06.02. | Target Healthcare REIT - Income and capital growth continuing | 259 | Indexed rent reviews continue to drive earnings growth and property valuation uplifts at Target Healthcare REIT. Meanwhile, tenant profitability remains strong, reflected in a continuing high level... ► Artikel lesen | ||
| 05.02. | Metals One - Black Schist moves to the next stage | 395 | Metals One announced on 31 January the results of the preliminary economic assessment (PEA) into its Black Schist project, compiled by Wardell Armstrong. Of its two deposits, the key economic driver... ► Artikel lesen | ||
| 05.02. | James Fisher (LSE: FSJ) - FY24 trading update implies progress towards targets in FY25 | 354 | James Fisher is starting to see the benefits of its transformation programme coming through. In H224, trading across the business was solid, supported by structural growth in end markets. FY24 underlying... ► Artikel lesen | ||
| 05.02. | Basilea Pharmaceutica (SIX: BSLN) records first commercial milestone payment from Japan | 360 | Basilea Pharmaceutica has announced the receipt of its first commercial milestone payment of CHF1.2m from partner Asahi Kasei Pharma (AKP) for reaching an undisclosed sales threshold in Japan for its... ► Artikel lesen | ||
| 04.02. | Finsbury Growth & Income Trust - Exciting times - more UK and zero overseas | 269 | Finsbury Growth & Income Trust's (FGT's) portfolio has changed considerably since 2019. There is a greater exposure to digital winners, which now make up close to two-thirds of the fund, a lower weighting... ► Artikel lesen | ||
| 04.02. | NWF Group (LON: NWF) - H1 profits up 25%, outlook encouraging | 354 | NWF Group increased H1 operating profit by 21% to £5.0m and retained a strong balance sheet with net cash of £11.4m (H123: £13.3m), driven by robust trading. The key drivers of growth were the Fuels... ► Artikel lesen | ||
| 03.02. | HgT - Transaction activity picked up in 2024 | 235 | HgT reported a robust 10.1% preliminary NAV total return (TR) in FY24 (of which 4.4% in Q424), which the company highlighted was primarily driven by the strong trading performance of the underlying... ► Artikel lesen | ||
| 03.02. | IRLAB Therapeutics - Phase I data supports IRL757's development | 263 | IRLAB Therapeutics has reported positive top-line data from one of the two ongoing Phase I clinical trials evaluating its third clinical-stage asset, IRL757, as a potential treatment for apathy. This... ► Artikel lesen | ||
| 03.02. | Sylvania Platinum - Cost control and production improvements | 1.481 | Sylvania Platinum's Q225 production increased by 7.4% on Q125, driving a 104% increase in EBITDA to US$6.7m, supported by cost control and a small increase in the average platinum group metals (PGM)... ► Artikel lesen | ||
| 03.02. | The Platform Group - Feedback from January 2025 CMD | 398 | At The Platform Group's (TPG's) January 2025 capital markets day (CMD), management provided an overview of the headline FY24 results (above guidance) and updated future guidance released that day. TPG... ► Artikel lesen | ||
| 31.01. | Herantis (HEL: HRTIS) presents positive Phase Ib update | 257 | Herantis Pharma has announced an encouraging update from its ongoing Phase Ib trial for lead asset HER-096, which is being developed as a potential disease-modifying treatment for Parkinson's disease... ► Artikel lesen | ||
| 31.01. | IRLAB Therapeutics (STO: IRLAB-A) reports positive Phase I data for IRL757 in elderly cohort | 297 | IRLAB Therapeutics has reported positive top-line data from one of two ongoing Phase I studies evaluating the drug candidate IRL757 as a treatment for apathy. This study, financed by the McQuade Center... ► Artikel lesen | ||
| 31.01. | IRLAB (STO: IRLAB-A) reports positive Phase I data for IRL757 in elderly cohort | 303 | IRLAB Therapeutics has reported positive topline data from one of two ongoing Phase I studies, evaluating the drug candidate IRL757 as a treatment for apathy. This study, financed by the McQuade Center... ► Artikel lesen | ||
| 30.01. | OSE (PAR: OSE) launches AI immunotherapy partnership | 233 | OSE has signed a strategic partnership with Scienta Lab, aiming to model inflammatory diseases and identify predictive biomarkers of efficacy for immunotherapies. Scienta Lab is a France-based leader... ► Artikel lesen | ||
| 29.01. | Dowlais Group - American Axle & Manufacturing agreed offer | 1.568 | In 2024, Dowlais Group exited its loss-making Hydrogen business and announced a strategic review of Powder Metallurgy. The group has now announced an agreed offer from American Axle & Manufacturing... ► Artikel lesen | ||
| 29.01. | Biomea Fusion - An innovative approach to diabetes and obesity | 415 | Biomea Fusion is a clinical-stage biopharmaceutical company developing novel small molecules to cure metabolic diseases. Its proprietary FUSION System platform has created a pipeline of covalent candidates... ► Artikel lesen | ||
| 29.01. | Alkane Resources - Ventis secundis | 338 | Alkane's Q225 quarterly activities report demonstrated production of 14,852oz Au via the processing of 269kt ore (cf guidance of 260-290kt) at a head grade of 2.25g/t (2.1-2.3g/t) and 84.2% metallurgical... ► Artikel lesen | ||
| 28.01. | Foxtons Group - Market share gains in Sales continues apace | 312 | Foxtons Group's FY24 trading update confirmed revenue and adjusted operating profit growth of c 11% and c 33%, respectively, reflecting the developing success of the company's strategic vision. This... ► Artikel lesen | ||
| 28.01. | Information Services Corporation (ISC: TSX) - Management guidance for FY25 | 331 | Information Services Corporation (ISC: TSX) announced its management guidance for FY25, with revenue of C$257-267m and adjusted EBITDA of C$89m-97m (FY24 guidance: revenue of C$240m-250m, adjusted EBITDA... ► Artikel lesen | ||
| 28.01. | CQS Natural Resources Growth and Income - A natural resources specialist worth preserving | 289 | CQS Natural Resources Growth and Income (CYN) is a differentiated closed-end investment company seeking opportunities across small- and mid-cap mining and resource stocks, which in our view deserves... ► Artikel lesen | ||
| 28.01. | Information Services Corporation (ISV: TSX) - Management guidance for FY25 | 300 | Information Services Corporation (ISV: TSX) announced its management guidance for FY25, with revenue of C$257-267m and adjusted EBITDA of C$89m-97m (FY24 guidance: revenue of C$240m-250m, adjusted EBITDA... ► Artikel lesen | ||
| 28.01. | Invesco Asia Trust - A patient Asian champion | 254 | Invesco Asia Trust (IAT) delivered a 12.4% NAV total return (TR) over the 12 months to end-December 2024, bolstered by the stock market rally in China and Hong Kong (to which IAT's managers patiently... ► Artikel lesen | ||
| 28.01. | Lords Group Trading (LSE: LORD) - FY24 trading update points to positive outlook | 288 | As a result of a tough trading environment, Lords Group Trading expects FY24 revenue to be £436m (FY23: £463m) and EBITDA to be 'slightly' below expectations. The merchanting business was down 3.6%... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
